

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

CHANGE IN COMPOSITION OF BOARD COMMITTEES

This announcement is made pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited in relation to the changes in composition of the board (the “**Board**”) committees of Innovent Biologics, Inc. (the “**Company**”) with effect from August 30, 2024:

- (a) Dr. De-Chao Michael Yu, an executive director of the Company (the “**Director**”), has been redesignated from the chairman to a member of the nomination committee of the Board (the “**Nomination Committee**”), and has resigned as a member of the remuneration committee of the Board; and
- (b) Mr. Shuyun Chen, an independent non-executive Director, has been redesignated from a member to the chairman of the Nomination Committee and has been appointed as a member of the audit committee of the Board.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China, August 30, 2024

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I – Yin Hsu, Dr. Kaixian Chen, Mr. Gary Zieziula, Dr. Shun Lu and Mr. Shuyun Chen as Independent Non-executive Directors.